Castle Biosciences Inc - relatórios financeiros (NASDAQ:CSTL) | MetaTrader

Abrir gráfico completo

Notícias

CEO da Castle Biosciences vende ações no valor de US$ 106.598

Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL)

Castle Biosciences apresenta dados de teste de melanoma em reunião da AAD

Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents

United Therapeutics Stock Surges 32% in 6 Months: Here's Why

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?

JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU

CFO da Castle Biosciences vende ações no valor de US$ 192 mil

Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k